I2-Imidazoline Ligand CR4056 Improves Memory, Increases ApoE Expression and Reduces BBB Leakage in 5xFAD Mice.

Recent evidence suggests that I2-imidazoline ligands have neuroprotective properties in animal models of neurodegeneration, such as Alzheimer's disease (AD). We recently demonstrated that the I2-ligand BU224 reversed memory impairments in AD transgenic mice and this effect was not because of reductions in amyloid-β (Aβ) deposition. In this study, our aim was to determine the therapeutic potential of the powerful analgesic I2-imidazoline ligand CR4056 in the 5xFAD model of AD, since this ligand has been proven to be safely tolerated in humans.

Education provision in community setting increases engagement with bowel cancer screening.

In the United Kingdom, colorectal carcinoma (CRC) is the third most prevalent and second most lethal cancer, accounting for 1 in 10 cancer deaths. To address this health burden, the NHS implemented a national screening programme to detect traces of blood in the stool of those at highest risk of CRC - men and women aged over 60. Preliminary data showed that the screening programme reduced CRC death by 16% overall and 23% in those who had returned their kit, highlighting the importance of patient engagement.